ProSomnus Sleep Technologies, a Pleasanton, CA-based non-CPAP Obstructive Sleep Apnea (OSA) therapy and Smart Sleep Medicine company, has received $38 million in strategic investment led by Catalio Capital Management.
Read More:LanzaJet Raises $47M in New Funding
The company plans to use the funds to speed up the global expansion of its technology-driven sleep health platform.
Under the agreement, Catalio, a leading healthcare-focused investment firm, has committed up to $38 million to support the development of next-generation remote patient monitoring and proprietary sleep diagnostic devices, fund clinical studies, and expand infrastructure to meet growing demand for patient-preferred sleep apnea therapies.
Len Liptak, CEO of ProSomnus, said Catalio’s investment supports the company’s mission to tackle obstructive sleep apnea with precise, data-driven solutions that benefit patients, doctors, and payers. He noted that demand for effective, affordable, and patient-preferred treatments is growing. This partnership will help ProSomnus expand access to care and further develop and validate its next-generation sensor-enabled devices. He added that the company looks forward to working with Catalio to speed up global adoption of Smart Sleep Medicine.
Jason Orchard, CFO of ProSomnus, said the $38 million commitment gives the company a strong financial foundation to grow while staying focused on patients. By investing in advanced remote monitoring, and thorough clinical studies, ProSomnus aims to measure success not just by market share, but by clear patient results. He added that these investments will help lower the cost of care, improve treatment effectiveness, and build a sustainable model for both shareholders and patients.
Dr. Nicholas von Guionneau of Catalio has joined the ProSomnus Board as an Observer. He said sleep medicine is moving toward data-driven, patient-preferred treatments, and ProSomnus is leading this shift with connected oral devices that are clinically effective, and widely used by patients. He added that Catalio is excited to support the global launch of the company’s next generation product and its broader vision for a scalable, connected sleep medicine platform.
About Catalio Capital Management, LP:
Founded in 2016 by CEO Len Liptak, ProSomnus is a pioneer and global leader in Smart Sleep Medicine, offering a technology-enabled, non-CPAP treatment for obstructive sleep apnea (OSA). OSA is a serious condition that affects more than 1 billion people worldwide and is linked to major health risks such as heart failure, stroke, and type 2 diabetes.
ProSomnus combines precision-made oral devices with advanced remote patient monitoring and data-driven diagnostics to improve the standard of care. Its platform delivers ongoing, nightly insights to support strong treatment adherence and proven patient results. The non-invasive, patient-preferred devices have shown strong safety and effectiveness in clinical studies. ProSomnus devices are FDA cleared, patented, and covered by commercial insurance, Medicare and TRICARE, reaching more than 200 million covered lives worldwide.
About Catalio Capital Management, LP:
Founded in 2020, Catalio Capital Management, LP is a New York–based investment firm focused on innovative healthcare investments across private, public, and credit markets. Catalio works exclusively with leading scientist-entrepreneurs from around the world who have strong academic and scientific backgrounds and have founded multiple successful companies based on their research. The firm has offices in New York, London, and Washington, D.C.
Read More:Eagle Wireless Raises $30M in Series B Funding
